Sr. Scientist / Engineer - Biologics Downstream at Bristol-Myers Squibb Company - Syracuse, NY Last seen 1 week ago
- Biologics Downstream (Req. 1002445) Bristol-Myers Squibb - Syracuse, New York The role of the Sr. Scientist/Sr. Engineer is to lead the tech transfer, process validation and clinical/ commercial manufacturing support activities for Third...more
Sr. Scientist / Engeer - Biologics Upstream at Bristol-Myers Squibb Company - Syracuse, NY Last seen 1 week ago
Sr. Scientist / Engineer - Biologics Upstream (Req. 1002446) Syracuse, NY The role of the Sr. Scientist/Sr. Engineer is to lead the tech transfer, process validation and clinical/ commercial manufacturing support activities for Third Party...more
Principal Scientist at Bristol-Myers Squibb Company - Princeton, NJ Last seen 2 weeks ago
As a member of a Bioanalytical Sciences team supporting biologic drug development, this individual will be responsible for managing a staff of 2-4 bioanalytical scientists in the development/validation of PK and immunogenicity assays on...more
Posted 7 hours ago by Admin.Bristol-Myers Squibb (NYSE: BMY), often referred to as BMS, is a pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger its predecessors Bristol-Myers and the Squibb Corporation. ...more
Posted 1 week ago by ruslan.david@gmail.com (Administrator)
In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers ...more
Posted 1 week ago by Someone
Data from AVERROES Trial of Investigational Drug Apixaban Will Be Presented During a Hot Line Session at Upcoming European Society of Cardiology Meeting Aug 25,more
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress .....
more...